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a b s t r a c t
NewWorld alphaviruses belonging to the family Togaviridae are classiﬁed as emerging infectious agents
and Category B select agents. Our study is focused on the role of the host extracellular signal-regulated
kinase (ERK) in the infectious process of New World alphaviruses. Infection of human cells by
Venezuelan equine encephalitis virus (VEEV) results in the activation of the ERK-signaling cascade.
Inhibition of ERK1/2 by the small molecule inhibitor Ag-126 results in inhibition of viral multiplication.
Ag-126-mediated inhibition of VEEV was due to potential effects on early and late stages of the
infectious process. While expression of viral proteins was down-regulated in Ag-126 treated cells, we did
not observe any inﬂuence of Ag-126 on the nuclear distribution of capsid. Finally, Ag-126 exerted a
broad-spectrum inhibitory effect on New World alphavirus multiplication, thus indicating that the host
kinase, ERK, is a broad-spectrum candidate for development of novel therapeutics against New World
alphaviruses.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The New World alphaviruses, Venezuelan equine encephalitis
virus (VEEV), Eastern equine encephalitis virus (EEEV), and
Western equine encephalitis virus (WEEV), can infect humans and
potentially cause encephalitic disease (Weaver and Reisen, 2010). In
2013, Latin America recorded multiple conﬁrmed cases of New
World alphavirus infections with a total of 19 patients hospitalized
for encephalitis. Among them, 3 patients died, 1 of whom had
conﬁrmed VEE (Carrera et al., 2013). Owing to their propensity to
cause naturally-occurring disease, these alphaviruses have been
classiﬁed as emerging infectious agents. The NewWorld alphaviruses
have the potential to be extremely infectious by the aerosol route and
have therefore been explored previously as potential bioweapons
(Zacks and Paessler, 2010). For this reason, VEEV and EEEV are
classiﬁed by the Centers for Disease Control (CDC) as Category B
select agents. There are currently no FDA-approved therapeutic
candidates or vaccines for the protection of humans from New
World alphavirus infections. The attenuated TC-83 strain of VEEV is
used to vaccinate select at-risk personnel; however, TC-83 has
concerns regarding safety and is considered to be a reactogenic
vaccine (Barrett and Stanberry, 2009). Around 40% of all vaccinees
have developed disease with some symptoms typical to that of
natural VEE infection (Volkova et al., 2008). Therefore, there are
ongoing efforts to establish a more effective and safer vaccine, some
of which include vaccine candidates derived from the V3526
attenuated strain of VEEV (Fine et al., 2010; Martin et al., 2010;
Paessler and Weaver, 2009; Sharma et al., 2011). FDA-approved
antiviral therapies for RNA viruses, such as ribavirin, have been
ineffective against VEEV and WEEV (Canonico et al., 1984), further
highlighting the importance of new therapeutic approaches as
medical countermeasures against New World alphaviruses.
Viruses rely on their host cell for the establishment of a
productive infectious cycle. Viruses are obligate pathogens that are
known to modulate and utilize many host events, including host
signal-transduction mechanisms. A deeper understanding of the
dynamics of the interactions between the host and the pathogen
can help in the identiﬁcation of novel targets for therapeutics. For
example, many alphaviruses have developed the ability to interfere
with the induction of the host cell antiviral response (Burke et al.,
2009; Garmashova et al., 2007). Animal models have also revealed
changes in gene expression in VEEV-infected mouse brains (Sharma
et al., 2008). We have demonstrated that host kinases, such as
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.09.005
0042-6822/& 2014 Elsevier Inc. All rights reserved.
n Correspondence to: National Center for Biodefense and Infectious Diseases,
George Mason University, Biomedical Research Lab, 10650 Pyramid Place, MS 1J5,
Manassas, VA 20110, USA. Tel.: þ703 993 9610; fax: þ703 993 4280.
E-mail address: anaraya1@gmu.edu (A. Narayanan).
Virology 468-470 (2014) 490–503
glycogen synthase kinase-3β (GSK-3β) and the inhibitor of nuclear
factor kappa-B kinase subunit beta (IKK-β), were modiﬁed upon
VEEV infection (Kehn-Hall et al., 2012; Amaya et al., 2014). Targeting
these kinases with small molecule inhibitors resulted in a decrease of
viral replication. Such observations underscore the potential of host-
based candidates as therapeutic targets for development of antivirals
against New World alphaviruses. The advantages conferred by host-
based therapeutics include a decreased potential for the develop-
ment of resistant strains and an increased probability of broad-
spectrum applicability to treat many viral indications. The concerns
around host-based therapeutics include a low threshold for toxicity
and hence, a requirement of a stringent analysis of inhibitor induced
toxicity proﬁles in the host.
The host MAPK, extracellular signal-regulated kinase (ERK),
responds to stress events including infection by directing multiple
downstream events like inﬂammation and cell death (Hong et al.,
2009; Hu et al., 2004; Xing et al., 2010). ERK exists as ERK1 and ERK2
(hereafter referred to collectively as ERK1/2), both of which have a
central position in the MAPK cascade, downstream in RAS-RAF-MEK-
ERK signal transduction (Roskoski, 2012a, 2012b). Brieﬂy, RAF kinases
act by phosphorylating and therefore activating MEK1 and MEK2
(collectively referred to as MEK1/2). MEK1/2 have dual speciﬁcity for
ERK1/2, phosphorylating ﬁrst at tyrosine and then threonine sites in
the activation segments of ERK1/2, causing subsequent activation
(Roskoski, 2012a, 2012b). Activated ERK1/2 act as protein-serine/
threonine kinases, phosphorylating more than 150 cytosolic and
nuclear substrates (Yoon and Seger, 2006; Shaul and Seger, 2007).
ERK1/2 form an activated dimer and translocate to the nucleus,
where they phosphorylate transcription factors regulating gene
transcription (Chuderland and Seger, 2005; Parra et al., 2005).
Multiple viruses are known to activate the RAS–RAF–MEK–ERK
signaling cascade in the host cell, and in many cases, this activation
has been correlated with viral replication (Pleschka, 2008).
Speciﬁcally, publications have implicated the ERK signaling pathway
in the regulation of viral replication and gene expression for
Coxsackievirus B3 (Luo et al., 2002), human cytomegalovirus
(Boldogh et al., 1990; Johnson et al., 2001), Junin virus (Rodríguez
et al., 2014), human immunodeﬁciency type 1 (Furler and
Uittenbogaart, 2010; Jacqué et al., 1998), coronavirus (Cai et al.,
2007), and inﬂuenza virus (Pleschka et al., 2001). Of particular
relevance to our studies, it was reported that Borna disease virus,
an RNA virus with high neurotropism, also manipulates the RAF/
MEK/ERK signaling cascade in vitro and appears to be essential for
viral spread (Hans et al., 2001; Planz et al., 2001). Here we
demonstrate that VEEV infection of human astrocytoma cells results
in the phosphorylation of multiple target proteins in the ERK
signaling cascade. Using a small molecule inhibitor of ERK, Ag-126,
we demonstrate that ERK1/2 phosphorylation plays an important
role in VEEV multiplication in infected cells. We provide data which
suggest that early and late events in the viral infectious cycle are
susceptible to ERK1/2 inhibitors. We extend our studies to the
virulent strains of VEEV, WEEV and EEEV, and demonstrate that
ERK1/2 signaling is a broad-spectrum requirement for New World
alphaviruses for the establishment of a productive infectious cycle.
Results
The RAF/MEK/ERK signaling cascade Is activated in VEEV-infected
cells
Our previous studies have indicated that host kinases including
IKK-β and GSK-3β were modulated in VEEV-infected cells and that
inhibition of these kinases with small molecule inhibitors resulted in
decreased viral multiplication (Amaya et al., 2014; Kehn-Hall et al.,
2012). We reported in our IKK-β study that multiple components,
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Fig. 1. ERK1/2 signaling is activated in TC-83 infected cells (A) Schematic of ERK signal transduction cascade – upstream activators and downstream targets.
(B) Quantiﬁcation of fold changes in phosphorylation status of target proteins in infected cells over uninfected cells as observed by RPPA. Signal intensities pertaining to
phosphorylated forms of proteins were calculated for mock-infected lysates and TC-83 infected lysates following imaging and quantiﬁcation of the RPPA slides. The values
were then used to calculate the fold change in phosphorylation in the infected samples over the mock-infected samples. (C) Western blot validation of ERK phosphorylation
in U87MG cells after infection with TC-83. Infected and mock uninfected cell lysates were collected at the time points indicated. β-actin was used as a loading control, and
three independent experiments were conducted. (D) Western blot validation of downstream substrate p90RSK phosphorylation. (E) Quantiﬁcation p-ERK1 and p-ERK2 in
infected cells from three independent experiments, normalized to β-actin and then compared to the mock at each time point. Bars indicate the mean and error bars represent
standard error.
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which collectively constitute the NFkB response (IKK-β, IκBα, p65),
were phosphorylated as part of a cascade activation process (Amaya
et al., 2014). Based on our previous lines of evidence, we hypothe-
sized that VEEV infection will activate other host phospho-signaling
cascades in infected cells and inhibition of speciﬁc events in those
cascades will have an effect on VEEV multiplication. We utilized a
reverse phase protein microarray (RPPA) approach to identify
changes in phospho-signaling cascades in VEEV-infected cells. We
have successfully used this approach in previous studies to identify
host events that are altered in virus-infected cells (Popova et al.,
2010a, 2010b; Wulfkuhle et al., 2006). The RPPA analysis was carried
out as described previously (Popova et al., 2010a, 2010b). Brieﬂy,
U87MG cells were either mock infected or infected with TC-83, the
attenuated strain of VEEV. Infections with TC-83 as indicated
throughout the manuscript involved exposure of the cells to the
virus for one hour unless otherwise indicated. We are referring to as
the time frame during which infection was allowed to happen after
which the viral overlay was removed. The antibodies used for the
analysis included a diverse range of signaling cascades such as
growth factor signaling, Akt signaling, NFkB signaling, and ERK
signaling. Fold differences in phosphorylation of the candidate
proteins seen in infected cells were calculated in comparison with
those in the uninfected cells. We observed that multiple signaling
molecules, which are part of the RAS–RAF–MEK–ERK signaling
cascade, were phosphorylated in VEEV-infected cells. The schematic
of the ERK signaling cascade is shown in Fig. 1A. The RPPA analysis
revealed that levels of phosphorylated ERK1/2 were 2-fold higher in
infected cells when compared with uninfected cells (Fig. 1B). The
data also indicated that the phosphorylation of the ERK1/2 upstream
activator MEK1/2 was also increased (Fig. 1B). Furthermore, many
downstream targets of ERK1/2 including Elk-1 (Cruzalegui et al.,
1999), p65 (Carter and Hunninghake, 2000), and Stat-1 (Zhang et al.,
2004) were activated in infected cells (Fig. 1B). Cumulatively,
preliminary RPPA data indicated that the ERK signaling cascade
was activated in VEEV-infected cells.
We performed independent validation experiments with a
focus on the phosphorylation status of ERK1/2 in TC-83 infected
U87MG cells. We carried out infections of U87MG cells and
collected total protein lysates at multiple time points between
5 min after the removal of initial viral inoculum (referred to hence
forth as the infection period) and 6 h after the infection period.
The lysates were subsequently fractionated by SDS-PAGE and
analyzed by Western blot using antibodies against phosphorylated
ERK1/2 (Thr202/Tyr204), unphosphorylated (total) ERK1/2, and β-
actin. The results showed an increased phosphorylation of ERK1/2
in the infected cells after the infection period (Fig. 1C, compare
lanes 1 and 7). Levels of p-ERK1/2 remained consistently higher in
the infected samples than the mock samples for the entire time
course which distinguished the phospho-proﬁle of ERK1/2 in
infected cells from the mock-infected control cells (Fig. 1C). We
performed additional validation experiments of the RPPA data by
subjecting our protein lysates to Western blot using antibodies
against p-p90RSK and β-actin. The activation proﬁle of p90RSK
paralleled that of ERK1/2 and agreed with the data obtained by the
RPPA process (Fig. 1D). To quantify levels of p-ERK1/2 in the TC-83
infected samples, three independent experiments were performed
and the fold changes over the mock samples in each experiment
averaged. Levels of p-ERK1 and p-ERK2 remained at around a
minimum of a 2-fold increase over the mock throughout the time
course (Fig. 1E). Our analysis of total ERK1/2 levels did not indicate
any signiﬁcant differences between mock and infected samples,
thus indicating the phosphorylation event to be independent of
total protein levels. Cumulatively, the data included in Fig. 1
suggest that infection of U87MGs with the attenuated TC-83 strain
of VEEV results in an activation of the ERK signaling cascade and
phosphorylation of ERK1/2 at early time points after infection.
Inhibition of ERK1/2 phosphorylation with Ag-126 inhibits viral
multiplication
Following validation of ERK phosphorylation in VEEV-infected
cells, we wanted to determine if this phosphorylation event was
essential for viral replication. To deﬁne the role of ERK1/2 in TC-83
infection, an inhibitor of ERK1/2 phosphorylation, tyrphostin Ag-
126, was employed. Tyrphostin Ag-126 (α-cyano-[3-hydroxy-
4nitro]cinnamonitrile), has been reported as a cell-permeable
inhibitor of lipopolysaccharide (LPS)-induced synthesis of tumor
necrosis factor–alpha (TNF-α) and nitric oxide (NOS) in murine
peritoneal macrophages (Novogrodsky et al., 1994). It also blocks
LPS-induced tyrosine phosphorylation of ERK and its substrates
and reduces the expression of iNOS and COX-2 in the lungs of rats
treated with carrageenan (Chatterjee et al., 2003). Before we
evaluated the antiviral efﬁcacy of Ag-126, we determined the
toxicity proﬁle of Ag-126. U87MG cells were seeded in 96-well
plates and 24 h later, increasing concentrations of Ag-126 were
added to wells in triplicate. DMSO was added as a negative solvent
control. The cells were maintained in the presence of Ag-126 for
24 h after which viable cells were quantiﬁed by measuring
luminescence in a Cell-Titer-Glo assay. The assay results showed
that the inhibitor was non-toxic to U87MG cells when compared
to the DMSO treated cells at the concentration range tested
(Fig. 2A). For all our subsequent experiments, we have used
Ag-126 at a concentration of 10 mM unless otherwise indicated.
As a next step, we wanted to test whether inhibiting ERK1/2
phosphorylation with Ag-126 would have an effect on TC-83
replication. U87MG cells were plated in a 96-well format and
were pretreated for 2 h with Ag-126. The media with the inhibitor
was removed and cells were infected with TC-83 for 1 h at 37 1C.
The viral overlay was removed at the 1 h time frame and media
with Ag-126 was added back to the cells. The cells were then
incubated for up to 24 h at 37 1C after which the supernatants
were collected to quantify infectious viral titers using plaque
assays. Controls included infected cells treated with DMSO. As
the concentration of Ag-126 treatment increased, the amount of
viral inhibition increased, demonstrating a dose-dependent
response (Fig. 2B). To determine whether the inhibitory effects of
Ag-126 were dependent on the multiplicity of infection (MOI),
U87MG cells were pretreated for 2 h with Ag-126 or DMSO alone
and infected with TC-83 at three different MOIs (0.1, 0.5, 1). The
cells were incubated for 24 h as described previously and the
supernatants were collected for quantiﬁcation of infectious viral
titers. Our data indicated that even at higher viral titers, Ag-126
continued to be inhibitory to viral multiplication (Fig. 2C).
To assess the effect of Ag-126 on expression of viral proteins, whole
cell lysates were obtained at 8 and 24 h post-infection, and subjected
toWestern blot analysis using antibodies to VEEV capsid and envelope
glycoproteins. At 8 h post-infection (8 hpi), VEEV capsid protein can be
detected in the treated cells; however, the amount of capsid protein
detected at this time point in the untreated cells was higher in the
untreated cells (Fig. 2D, compare lanes 1 and 2). The difference
between the amounts of capsid protein produced in Ag-126 treated
versus untreated cells was more prominent at the 24 h time point
(compare lanes 3 and 4). While we were unable to detect the VEEV E2
glycoprotein (GP) at 8 hpi, we could detect fairly robust expression of
glycoprotein in TC-83 infected, untreated cells when compared to
treated cells at the 24-hour time point (Fig. 2D, lanes 3 and 4). We
quantiﬁed the differences of treated and untreated cells at the 24-hour
time point in two independent experiments and found that Ag-126
treatment modestly reduced capsid expression, and had a greater
effect on GP expression (Fig. 2D). This indicated that decrease in viral
structural protein levels by Ag-126 treatment may be partially
responsible for decreased viral titers. We also conducted Western blot
analysis on infected and Ag-126 treated and infected cell lysates to
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ensure that Ag-126 treatment did indeed inhibit phosphorylation of
ERK1/2. Using antibodies against phosphorylated ERK1/2 (Thr202/
Tyr204), unphosphorylated (total) ERK1/2, and β-actin, we were able
to document a decrease in the amount of phosphorylated ERKs at all
time points tested in the presence of Ag-126 (Fig. 2E).
We performed a similar inhibition efﬁcacy study in Vero cells to
determine if the inhibition we observed in U87MG cells was a cell
type dependent phenomenon. To that end, we ﬁrst evaluated the
cytotoxicity of Ag-126 in Vero cells and determined that up to 50 mM
concentrations, Ag-126 did not evoke any cytotoxic responses
(Fig. 3A). We then determined if Ag-126 could inhibit TC-83 multi-
plication in Vero cells by pretreating cells with Ag-126 for 2 h and
then infecting with TC-83. Infectious titers were measured by plaque
assays at 24 h post the infection period. The result shown in Fig. 3B
indicates that Ag-126 could inhibit TC-83 even in a permissive cell
line such as Vero cells, albeit, the extent of inhibition being lesser
than what we observed in U87MG cells. Cumulatively, our data
suggested that at nontoxic concentrations, Ag-126 inhibited ERK1/2
phosphorylation, decreased viral protein expression and negatively
inﬂuenced TC-83 multiplication in infected cells.
Inhibition of ERK1/2 phosphorylation with Ag-126 inhibits nuclear
accumulation of ERK, but does not interfere with nuclear
accumulation of VEEV capsid protein
Phosphorylated ERK1/2 has both nuclear and cytosolic targets,
but typically is known to dimerize and translocate to the nucleus
where it acts on multiple transcription factors (Roskoski, 2012a).
Inhibition of ERK1/2 phosphorylation by small molecule inhibitors
affected nuclear translocation of ERK1/2 (Roskoski, 2012a). There-
fore, to conﬁrm that Ag-126 treatment indeed resulted in
decreased phosphorylation of ERK1/2 in U87MG cells, we inves-
tigated the intracellular p-ERK1/2 localization during VEEV infec-
tion in the presence or absence of Ag-126 at different time points
using confocal microscopy as described previously (Amaya et al.,
2014). Brieﬂy, U87MG cells were seeded in 8-well chambered
slides and infected with TC-83 virus. At 6 and 24 h after the
infection period, the cells were ﬁxed and probed with antibodies
to ERK1/2 and VEEV capsid. At 6 h, nuclear enrichment of p-ERK1/2
was observed in 71% of cells that were infected with TC-83 (Fig. 4A).
We deﬁned nuclear enrichment by a visual assessment, in which
p-ERK1/2 was localized to the nucleus. In contrast, 38% of mock
cells showed enrichment, whereas the Ag-126 treated cells had 22%
enrichment. Therefore, treatment with Ag-126 resulted in a
decrease in nuclear p-ERK1/2, thus attesting to an inhibition of
ERK phosphorylation. This observation added support to the data
presented in Fig. 2E.
At 24 h, 30% of TC-83 infected cells demonstrated a nuclear
enrichment of p-ERK1/2, but only 16% of the mock-infected cells
showed nuclear ERK1/2 (Fig. 4B). Capsid staining was detected in
90% of cells exposed to TC-83 virus, but not treated with Ag-126. In
comparison, capsid staining was reduced by 68% in the infected,
Ag-126 treated cells. While overall capsid staining was reduced in
Ag-126 treated cells, we did not observe any difference in the
Fig. 2. Inhibition of ERK1/2 phosphorylation reduces TC-83 replication and leads to lowered virus protein expression. (A) U87MG cells were treated with Ag-126 for 24 h,
and the Cell-Titer-Glo assay was conducted. Luminescence was measured and the values indicated as luminescence units in the Y-axis. The concentrations of the drug that
were used in this experiment are indicated in the X-axis. DMSO alone was used as a negative control, at 0.1% concentration. (B) U87MGs were pretreated Ag-126 for 2 h. Cells
were infected with TC-83 for one hour (MOI:0.1). The conditioned media was then added back onto the cells and 24 hpi the supernatants were collected. The graph portrays
the results of three independent experiments. (C) Cells were treated with 10 μM Ag-126 or DMSO alone and infected at either an MOI of 0.1, 0.5, or 1. Conditioned media was
added back to the cells after the one hour infection period, and left until supernatants were collected at 24 hpi. (D) Whole cell lysates were obtained from U87MG cells after
infection with TC-83 (MOI:1). Cells were infected in the presence or absence of Ag-126 treatment (10 μM). Infected cell lysates were collected at 8 hpi and 24 hpi. Amounts of
β-actin were used as a loading control. Data in the bar graph is representative of duplicate experiments at the 24 hpi time point. (E) Cells were infected with TC-83 (MOI:1)
and either untreated or treated with Ag-126. Total protein lysates were obtained at the indicated time points and analyzed by Western blot for phosphorylation status of
ERK1/2.
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distribution of capsid between the nucleus and cytoplasm of
infected cells, regardless of Ag-126 treatment thus indicating that
ERK1/2-mediated signaling events did not play a role in the
nuclear-cytoplasmic transport of VEEV capsid protein in infected
cells. Cumulatively, our microscopy studies, while attesting to the
inhibitory action of Ag-126 in negatively inﬂuencing the nuclear
accumulation of ERK1/2, did not support the potential of ERK-
mediated phosphorylation to control nuclear-cytoplasmic trans-
port of VEEV capsid protein.
Treatment with Ag-126 interferes with viral replication kinetics
Our study thus far, has analyzed inhibition of TC-83 multi-
plication by Ag-126 as a static phenomenon, at 24 h after the
infection period. It would be more informative to determine if the
overall replication kinetics of the virus was impacted by Ag-126
treatment. To this end, U87MG cells were pre-treated with Ag-126
for 2 h or DMSO alone as a control. Cells were infected with TC-83,
supernatants were collected at multiple time points (3, 6, 16, 24
and 30 h post-infection), and plaque assays were performed. The
results, as shown in Fig. 5A, demonstrate an overall decrease in
viral replication kinetics that could be clearly observed as early as
6 h post the infection period and was not exacerbated over
subsequent time points. We performed time-of-addition experi-
ments in an attempt to identify speciﬁc time frames in the
infectious cycle when the inhibition by Ag-126 could be detected.
Cells were treated with either Ag-126 or DMSO alone, at the
indicated times (Fig. 5B). All supernatants were collected at 24 h
and quantiﬁed for infectious viral titers. We observed that when
cells were pretreated with Ag-126 two hours before infection (2 h
pre), robust inhibition was apparent. While Ag-126 continued to
be inhibitory when added 2 hpi (2 h post), the extent of inhibition
was not as robust as the 2-hour pretreatment. When the drug was
added at 4 hpi, the inhibitory potential decreased (Fig. 5C). We
also observed a modest, but statistically signiﬁcant reduction in
titers when drug was added at 8 h post the infection period, which
could potentially implicate Ag-126 in late events as well. However,
it is unclear whether the apparent inhibition seen at the 8 h time
point was due to late events in the ﬁrst round of viral multi-
plication, or the early events of the second round of multiplication.
Cumulatively, our experimentation with the addition of Ag-126 at
Fig. 3. Inhibition of ERK1/2 phosphorylation with Ag-126 is not cell type dependent.
(A) VERO cells were seeded at 30,000 cells per well in a 96-well plate and different
concentrations of Ag-126 applied. Cell-Titer-Glo assay was performed the next day.
(B) VERO cells seeded at 10,000 cells per well in a 96-well plate were pre treated for 2 h
with Ag-126 (50 μM) and infected with TC-83 (MOI:0.1) for one hour. Conditioned
media was replaced and supernatants collected at 24 hpi were subjected to
plaque assay.
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Fig. 4. Ag-126 treatment decreases nuclear pools of p-ERK1/2 without inﬂuencing capsid localization in the nucleus. U87MG cells were seeded in a 8-chambered slide and
infected with TC-83 (MOI:1). For every variable, at least two independent wells were analyzed. Cells were ﬁxed at 6 (A) and 24 (B) hpi and stained with antibodies against
VEEV capsid (red) and p-ERK1/2 (green). The slides were also stained with DAPI to stain the nucleus (blue). Images were collected using a Nikon Eclipse TE2000-U and
acquired with a 60X objective. Images are representative of multiple ﬁelds that were imaged for each variable. Three independent experiments were conducted.
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Fig. 5. Ag-126 treatment exerts an inhibitory effect on viral replication kinetics during the early stages of the infectious process. (A) U87MG cells were seeded in 96-well
plates and treated with Ag-126 (10 mM). Cells treated with DMSO were maintained as controls. The cells were infected with TC-83 (MOI:0.1) and supernatants were obtained
at multiple time points after infection and quantiﬁed by plaque assays. The Y-axis indicates the PFU/ml titer of infectious virus and the X-axis indicates the time points at
which supernatants from drug/DMSO treated cells were analyzed. (B) Time of addition study - Ag-126 was added to U87MG cells either at 2 h prior to infection or at 2, 4, and
8 hpi. All infections took place at the same time, for one hour (MOI:0.1). The gray arrows indicate presence of Ag-126 in different samples (2, 4, and 8 hpi). Supernatants from
all conditions were collected at 24 hpi and quantiﬁed by plaque assays. (C) Y-axis refers to titers of infectious virus and X-axis indicates the time points at which drug was
introduced. Pre/post indicates a 2 h pretreatment, and replacement of media with inhibitor after the one hour infection period. The experiment was conducted
4 independent times. (D) TC-83 was incubated directly with Ag-126 for 1 h in the absence of cells prior to quantiﬁcation by plaque assays (without cells). As a control,
U87MG cells were infected with TC-83 in the presence of Ag-126 (with cells). Plaque assays were performed with VERO cells using supernatants from both conditions for
quantiﬁcation of infectious virions. Differences between TC-83 and TC-83þAg-126 without cells was not statistically signiﬁcant. (E) Detailed time of addition assay
schematic. (F) Time of addition outcomes are indicated. Y-axis indicates infectious viral titers and X-axis indicates time frames when Ag-126 was present. Results from three
independent experiments are shown in the ﬁgure.
Fig. 5. (continued)
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multiple time points after the infection period revealed that Ag-
126 may affect viral multiplication at early and late time frames of
the infectious process. The fact that the pretreatment strategy was
the most efﬁcacious in our hands could also imply that the longer
the drug is available in the system, the greater the extent of
inhibition observed.
At this time, we wanted to determine if Ag-126 was directly
virucidal in nature, which may also contribute to the observed
inhibition with a concentration towards the early time points. To
address this possibility, we performed a modiﬁed plaque reduction
neutralization assay. We incubated TC-83 directly with Ag-126 for
1 h at room temperature. After the incubation, the infectivity of
the virus was quantiﬁed by plaque assay. Our data indicated that
when Ag-126 was added to U87MG cells in the presence of virus,
there was inhibitory action as expected; this acted as our positive
control for the inhibitory potential of Ag-126 (Fig. 5D). However,
when we incubated the virus directly with Ag-126 as a part of the
same experiment, in the absence of U87MG cells and then
quantiﬁed the infectivity of the virus by plaque assay, there was
no difference between virus exposed to the drug and virus not
exposed to the drug, thus indicating that Ag-126 did not exert any
direct virucidal activity.
To gain more insight into the antiviral effects of Ag-126 on
TC-83 multiplication, we performed a slight variation of the time
of addition study in which the drug was made available only for
limited blocks of time. This experimental organization involved
adding the drug at different time points followed by removing the
drug and replacing with fresh media (Fig. 5E). U87MG cells were
treated with Ag-126 at the indicated times and all supernatants
were collected at 24 h and quantiﬁed for infectious viral titers
(Fig. 5E). We observed that when cells were pre treated for 2 h
(pre), there was a robust inhibition of TC-83 (Fig. 5F). However, the
inhibition was even more robust when the drug was added
directly after the one hour infection period for one hour
(0–1 hpi). Later time points were modestly efﬁcacious. Paralleling
our earlier observation, addition of the drug at the 6–8 h window
resulted in a statistically signiﬁcant decrease in viral multiplica-
tion. This may be due to the inﬂuence of Ag-126 on late stages of
viral multiplication or reﬂective of the early events during the
second round of viral multiplication.
Treatment with Ag-126 decreases the amount of VEEV glycoprotein in
the endoplasmic reticulum
We attempted to determine whether inhibition of viral multi-
plication by Ag-126 may also be a result of aberrant transport and/
or localization of structural proteins such as the glycoproteins to
the endoplasmic reticulum (ER) and the golgi apparatus (Snyder
and Mukhopadhyay, 2012). To that end, we performed confocal
microscopy experiments using antibodies to the ER and the golgi
apparatus in the context of TC-83 infection, with and without Ag-
126 to assess glycoprotein distribution in the ER and Golgi. We
carried out this experiment using VEEV glycoprotein antiserum
and analyzed the distribution of the glycoprotein in the ER and
golgi at 1, 2, 4 and 6 h post the infection period. In our hands, we
were able to detect glycoprotein in the ER at the 1 h time point
and the ER signal steadily decreased during the time course of
analysis (Fig. 6A and B). We were not able to observe any distinct
colocalization of glycoprotein with the golgi apparatus within the
time frames included in our study (Fig. 6A). In the presence of Ag-
126, we noticed that the glycoprotein signal in the ER was reduced
at the 1 h time point and the difference in the ER signal between
the treated and untreated cells increased by the 2 and 4 h time
points suggesting that Ag-126 may have an effect on the ER
localization of VEEV glycoprotein.
Activation of ERK1/2 increases viral replication of VEEV
We hypothesized that if inhibition of ERK1/2 activation
resulted in down-regulation of VEEV multiplication, activation/
priming of ERK1/2 could contribute to an up-regulation of VEEV
multiplication. We employed a MAPK activator of ERK, Ceramide
DAPI ER α-glycoprotein Merge
1hpi: 2hpi: 4hpi: 6hpi:
cells counted: 69 103 86 83
TC-83 infected: 36 39 52 59
co-localization: 13 11 13 9
% localization: 36.1 28.2 25 15.3
cells counted: 96 122 131 87
Ag-126 + TC-83 infected: 51 53 82 53
co-localization: 12 10 11 9
% localization: 23.5 18.9 13.4 17.0
DAPI Golgi α-glycoproteinMerge
Infected
Mock
Fig. 6. Inhibition of ERK1/2 phosphorylation with Ag-126 results in less VEEV glycoprotein in the endoplasmic reticulum. U87MG cells were seeded in a 8-chambered slide
and infected with TC-83 (MOI:1). For every variable, at least three independent wells were analyzed. (A) Cells were ﬁxed at 1, 2, 4, and 6 hpi and stained with antibodies
against VEEV glycoprotein (red) and an endoplasmic reticulum (ER) marker (green). The slides were also stained with DAPI to stain the nucleus (blue). Slides were also ﬁxed
and stained with a golgi marker (green) at the same time points. Images were collected using a Nikon Eclipse TE2000-U and acquired at 60 objective. Images are
representative of multiple ﬁelds that were imaged for each variable. Two independent experiments were conducted. (B) Cells from triplicate wells in two experiments were
counted at random for co-localization of VEEV glycoprotein and the ER in the presence and absence of Ag-126.
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C6 (Raines et al., 1993), to prime the cells and activate ERK1/2
phosphorylation prior to infection. As a ﬁrst step, we assessed the
toxicity of the compound in U87MG cells and found no loss of
viability at 1 μM concentration of the compound (Fig. 7A). Treat-
ments greater than or equal to 5 μM, however, had a noticeable
level of toxicity. Therefore, we decided to proceed with 0.1 μM
treatments for analysis of viral replication kinetics when ERK was
activated prior to infection. To validate that Ceramide C6 treatment
was activating ERK1/2 under our experimental conditions, we
collected whole cell protein lysates at multiple time points in the
presence or absence of Ceramide C6 and performed Western blot
analysis. The data indicated that Ceramide C6 treatment increased
the amount of phosphorylated ERK1/2 at 0.1 μM and 1 μM treat-
ments. Addition of 1 μM Ceramide C6 resulted in a earlier activa-
tion of ERK signaling (Fig. 7B, compare lanes 1 and 6), than 0.1 μM
treatment conﬁrming that Ceramide C6 does indeed activate
ERK1/2 signaling in this cell type.
To determine if Ceramide C6-based activation of ERK prior to
infection contributed to an increase in viral multiplication, U87MG
cells were treated for 2 h with either DMSO alone or 0.1 μM
Ceramide C6 and then infected with TC-83 for 1 h. Supernatants
were collected at 6, 8, and 16 hpi and quantiﬁed by plaque assay.
Our data indicated that virus titers were statistically signiﬁcantly
higher with Ceramide C6 treatments at the 6 h analysis point
(Fig. 7C). By 16 h, the Ceramide C6-treated samples had more than
a 2-log increase over the DMSO samples. We then assessed the
effect of Ceramide C6 treatment on the expression of viral
proteins. We saw a modest increase of VEEV capsid and
glycoprotein (GP) when cells were treated with 0.1 μM Ceramide
C6 before infection with TC-83 (Fig. 7D). Two independent
experiments were conducted and protein levels normalized to
β-actin quantiﬁed from both experiments. The average is shown
by the bars in Fig. 7D.
We next wanted to determine if activation of ERK1/2 had an
effect on the amount of viral RNA produced in the treated cells. To
assess the levels of intracellular viral RNA, we performed quanti-
tative RT-PCR (qRT-PCR) with VEEV speciﬁc primers. At 16 hpi,
where we saw the greatest difference of infectious viral titers, we
isolated intracellular RNA and subjected it to qRT-PCR analysis. The
genomic copies did not show any noticeable differences in the
viral RNA accumulation in the cells dependent on Ceramide C6
treatment (Fig. 7E). The supernatants that corresponded to the
16 h time point that was analyzed by the PCR method was
subjected to plaque assay to quantify infectious virus in those
same supernatant samples. Interestingly, the plaque assays
revealed an increase in the infectious viral titers in the presence
of Ceramide C6, although viral RNA levels were similar to the
DMSO control (Fig. 7E).
U87MG cells show improved Host-cell survival with Ag-126 treatment
We assessed whether Ag-126 treatment resulted in a reduction
of cytopathic effects (CPE) in context of TC-83 infection. Our earlier
experiments using host-based inhibitors of TC-83 multiplication
have alluded to the possibility of increased survival of infected
cells when the kinetics of viral multiplication are decreased
Fig. 7. Activation of ERK1/2 increases TC-83 replication kinetics. (A) U87MG cells were seeded in a 96-well plate, treated with Ceramide C6 for 24 h, and the Cell-Titer-Glo
assay was conducted to quantify cell viability. Luminescence (indicated in the X-axis) was measured and indicates cell viability. Y-axis indicates the concentration of drug
used. Mock and DMSO alone were used as controls. (B) Western blot analysis of 0.1 μM Ceramide C6 and 1 μM Ceramide C6 treatments on the phosphorylation status of
ERK1/2. Lysates were collected at 5, 10, and 30 min post-treatment, and 1, 2 h post-treatment. (C) U87MG cells were pretreated with 0.1 μM Ceramide C6 for 2 h and then
infected with TC-83 (MOI:0.1). Supernatants were collected at 6 hpi, 8 hpi, and 16 hpi (X-axis) and quantiﬁcation of infectious virus (Y-axis) was performed by plaque assays.
(D) Western blot analysis of Ceramide C6 treatment on viral proteins at 24 h post infection. Two independent experiments are averaged and shown as bars. (E) qRT-PCR
results of VEEV genomic copies at 16 hpi. To the right, the supernatants from the same exact wells examined in the qRT-PCR for intracellular genomic copies were subjected
to plaque assay to quantify infectious virus.
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(Amaya et al., 2014). To test whether Ag-126 treatment reduced
CPE in TC-83 infected U87MG cells, we imaged infected, untreated
cells and infected, Ag-126-treated cells 24 hpi (Fig. 8A). The
infected, Ag-126-treated cells (panels D, H and L) appeared to be
healthier than the infected, untreated cells (panels C, G and K)
and phenotypically resembled the mock infected, untreated cells
(A, E and I). Ag-126 treatment by itself did not change the
morphology of the cells (B, F and J) when compared to the mock
infected, untreated cells. Next we adopted a quantitative cell
survival assay to verify increased cell viability when treated with
Ag-126. In the survival assay, we measured the fraction of live cells
by Cell-Titer-Glo at 24 and 48 hpi in the presence and absence of
Ag-126 (Fig. 8B and C). At 24 hpi, infected cells treated with DMSO
alone dropped to 75% of the luminescence seen in the uninfected
cells. However, Ag-126-treated cells showed 11% more lumines-
cence when compared to DMSO alone. At 48 hpi, treated cells had
32% more survival than the DMSO alone control. Collectively, the
data supports the idea that in conjunction with exerting antiviral
Fig. 8. Inhibition of ERK phosphorylation during TC-83 infection improves survival of U87MG cells. (A) U87MG cells were seeded in a 12-well plate and infected with TC-83
(MOI:1). Treatment of Ag-126 was included at 10 μM. DMSO was maintained as a negative control. Images were taken at 24 hpi, with controls being Ag-126 treatment alone
and untreated uninfected cells. Rows A–D, E–H and I–L represent biological triplicate experiments. The conditions in each panel for every column are indicated in the table
above the images. (B and C) U87MG cells were seeded in white walled 96 well plates and infected with TC-83, with or without Ag-126 treatments (10 μM). At 24 hpi (B) and
48 hpi (C), biological triplicate wells were subjected to Cell-Titer-Glo assay. X-axis indicates the amount of cell survival and Y-axis indicates the drug treatment conditions.
All experiments were repeated three independent times.
Fig. 9. Inhibition of ERK1/2 activation with Ag-126 reduces replication of virulent
alphaviruses. U87MG cells were seeded in a 96 well format and pretreated for 2 h
with Ag-126 (10 μM) or DMSO alone. The cells were infected with VEEV TrD, EEEV
strain GA97, WEEV strain California 1930 (MOI:0.1). Supernatants collected at
24 hpi were quantiﬁed by plaque assay. X-axis refers to infectious viral titers and
Y-axis indicates the nature of the virus and type of treatment that was used.
Fig. 10. Inhibition of MEK1/2 with small molecule inhibitors have different effects
on TC-83 replication. (A) Toxicity was assessed at 24 h post-treatment by Cell-Titer-
Glo assay. (B) U87MG cells were treated with the inhibitors for 2 h and then
infected with TC-83 (MOI:0.1) for one hour. Supernatants collected at 24 hpi were
subjected to plaque assay.
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activity, inhibition of ERK phosphorylation during early stages of
infection by inhibitors, such as Ag-126, can contribute to increas-
ing survival of infected cells.
Ag-126 treatment down regulates viral multiplication of three
virulent alphavirus strains
We extended our analysis of Ag-126 dependent inhibition of
ERK1/2 phosphorylation to the virulent strains of New World
alphaviruses. In this experiment, we utilized the Trinidad Donkey
(TrD) strain of VEEV, the GA97 strain of EEEV, and the California
1930 strain of WEEV. To this end, U87MG cells were pretreated
with DMSO or Ag-126 and then infected with each of the virulent
strains. All infections were performed for 1-hour and conditioned
media were replaced and the supernatants collected 24 h later.
Plaque assays were performed to quantify infectious viral particles
(Fig. 9). Addition of Ag-126 treatment reduced viral titers of VEEV
TrD from 8.67108 PFU/ml to 8.17104 PFU/ml, a 4-log decrease.
In the case of EEEV, treatment resulted in an overall 1-log drop,
from 1.481010 PFU/ml to 9.17108 PFU/ml. For WEEV, Ag-126
treatment contributed to a 2-log decrease in viral titer from
2.83105 PFU/ml to 5.33103 PFU/ml. The results supported
the hypothesis that ERK1/2 was likely to be a broad-spectrum
target for the development of antivirals against New World
alphaviruses.
MEK1/2 inhibitors differ in their abilities to decrease TC-83
multiplication
Finally, we wanted to know if other inhibitors of the Ras–RAF–
MEK–ERK signaling cascade would similarly affect VEEV multi-
plication. To this end, we employed various MEK1/2 inhibitors to
characterize their effect on TC-83 multiplication in our cells. We
chose to evaluate PD184352, GSK1120212, AZD6244, and U0126.
Among these, GSK1120212 is already FDA approved for cancer
therapy, and would therefore be a strong candidate to repurpose
as an antiviral therapeutic for alphaviruses. The toxicity proﬁle of
each compound was evaluated at 50 and 20 μM concentrations
in U87MG cells by Cell-Titer-Glo assay as described previously.
PD184352 showed a signiﬁcant decrease in cell viability to 74% at
50 μM treatment, but was relatively nontoxic at 20 μM (Fig. 10A).
All other compounds were non-toxic at both concentrations.
U87MG cells were then pre treated with 50 μM of each MEK
inhibitor, except for PD184352 which was tested at 20 μM, and
then infected with TC-83 virus. Supernatants were collected 24 h
later and subjected to plaque assay. The results showed that
GSK1120212 was able to decrease VEEV multiplication by up to
2 logs while AD184352 was also effective, but to a lesser extent.
U0126 and AZD6244 were not effective at inhibiting TC-83 multi-
plication in this system (Fig. 10B). Cumulatively, our data indicated
that inhibition of ERK1/2 signaling is an attractive option to inhibit
alphavirus multiplication in human cells.
Discussion
Innate immune responses that are established early following
exposure to infectious agents play an essential role in pathogen
control and protection of the host. Such innate immune mech-
anisms are shaped by host phospho-signaling responses that
undergo fairly elaborate modulation upon cellular insult, which
includes exposure to infectious agents. Virus infection is well
documented to activate many host signaling responses that often
shift the balance between host survival and cell death. Many
viruses have been known to hijack some of these intrinsic host
responses to enable establishment of a productive viral infection.
Often such hijacking mechanisms involve additional host
responses that are also modiﬁed, cumulatively resulting in a
suppressed host environment where the virus can multiply with-
out interference by the innate host protective mechanisms such as
interferon responses. In fact, New World alphaviruses including
VEEV and WEEV have been known to suppress the host interferon
response by a mechanism that involves the viral capsid protein
(Atasheva et al., 2010; Peltier et al., 2013). As part of the
pathogenesis, New World alphaviruses have also been known to
trigger apoptosis of the infected cells, mediated by host signaling
pathways (Grifﬁn and Hardwick, 1997). Our previous studies using
GSK-3β and IKK-β inhibitors have established that inhibition of
host phospho-signaling events exerts an inhibitory effect on viral
multiplication in infected human cells (Amaya et al., 2014; Kehn-
Hall et al., 2012; Narayanan et al., 2012).
In the current study, we have provided evidence for the
activation of ERK1/2 phosphorylation at early time points follow-
ing exposure to the TC-83 strain of VEEV (Fig. 1). Our observation
that phosphorylated ERK1/2 increased in TC-83 infected cells
while there were no signiﬁcant changes observed in the levels of
total ERK1/2 protein indicated that the increase in phosphorylated
forms was independent of de novo protein synthesis (Fig. 1C).
Small molecule inhibitors of ERK1/2 phosphorylation, such as Ag-
126, when used in the nontoxic range, have the potential to inhibit
viral multiplication (Fig. 2). We have observed that the inhibition
is mediated through interruption of potentially early and late
events in the infectious process. Our data suggests that the
compound is not directly virucidal. We hypothesize that Ag-126
is likely to interfere with a host process that is essential for the
internalized virus to go through the subsequent steps of capsid
shedding and release of viral nucleic acid into the cytoplasm of the
cell. Additional steps in the inhibitory process may involve
abberations in packaging and viral egress. Ongoing research to
address these possibilities will include analysis of host events that
are essential for the intracellular transport of the virus, which may
involve cytoskeletal dynamics.
The hypothesis does not negate the possibility of direct ERK-
mediated modiﬁcation of viral proteins. For example, viral non-
structural proteins (nsPs) may be phosphorylated by host kinases
that inﬂuence their function. One such alphavirus protein that is
known to be heavily phosphorylated is nonstructural protein 3
(nsP3) (Li et al., 1990; Peränen et al., 1988; Vihinen and Saarinen,
2000). nsP3 is a critical regulator of negative strand synthesis and
affects virulence. However, the exact role of nsP3 in the viral
infectious cycle continues to remain unknown. Our earlier studies
have indicated that nsP3 may be phosphorylated by IKK-β. We will
be characterizing the phosphorylation status of nsP3 in the
presence of inhibitors, such as Ag-126, because nsP3 contains
other potential phosphorylation sites. These interesting aspects
are currently under investigation in our laboratory. In addition, it
appears that localization of E2 glycoprotein to the ER of infected
cells may be affected by Ag-126 (Fig. 6). It is therefore interesting
to speculate that Ag-126 may have an effect on viral particle
assembly and packaging.
Our studies suggest that inhibition of ERK phosphorylation may
also contribute to increase in survival of infected cells and
decrease in CPE following alphavirus infection (Fig. 8). Viruses
such as Varicella-Zoster virus (VZV) have been documented to
control apoptosis of infected cells by modulating multiple aspects
of the apoptotic signaling responses, often culminating in differ-
ential phosphorylation of key effector molecules like BAD, BAX,
BIM, etc. (Liu and Cohen, 2014). Interestingly, it was demonstrated
that the VZV protein ORF12 triggered the phosphorylation of ERK
in order to inhibit apoptosis (Liu et al., 2012). It would be
informative to quantify the status of various apoptotic events in
VEEV-infected cells in the presence and absence of effective
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inhibitors like Ag-126 to determine mechanisms that mediate cell
death of infected cells.
Our observation that MEK and ERK are phosphorylated in
VEEV-infected cells and ERK inhibitors effectively interfere with
viral multiplication open the doors for FDA-approved MEK and
ERK inhibitors including Trametinib, Selumetinib, and Cobemeti-
nib, for repurposing as antivirals with a novel indication as New
World alphavirus therapeutics. Repurposing such MEK and ERK
inhibitors is additionally attractive because of our evidence that
inhibition of ERK has a broad-spectrum effect on the multiplica-
tion of all three New World alphaviruses (Fig. 9). In our hands, at
least one other FDA approved inhibitor of the MEK–ERK cascade
was efﬁcacious at inhibiting VEEV multiplication even though Ag-
126 had a better inhibitory potential (Fig. 10).
The RPPA analysis identiﬁed many signaling nodes in the RAS-
RAF-MEK-ERK signaling cascade as being phosphorylated in TC-83
infected cells. We have focused the current study only on ERK
and its phosphorylation status. This study opens new avenues of
exploration on the consequences of the phosphorylation of
additional targets in this cascade on alphavirus replication. For
example, p90RSK phosphorylation has been demonstrated to
be intimately associated with replication of SARS-coronavirus
(Mizutani et al., 2006). It would be interesting to determine
whether inhibitors of these multiple ERK phospho-signaling nodes
will exert a synergistic and more potent inhibition of the virus
when used in a combinatorial capacity.
Methodology
Cell culture
Human astrocytoma cell (U87MG cells) and African green
monkey kidney epithelial cells (VERO cells) were maintained in
DMEM supplemented with 10% Fetal Bovine Serum (FBS), 1%
Penicillin/Streptomycin, and 1% L-Glutamine at 37 1C and 5% CO2.
Viral infections
Cells were seeded in a 96-well plate in order to attain
conﬂuence within 24 h. The media was removed prior to infection
and saved and is referred to as conditioned media. The cells were
infected for 1 h at 37 1C to allow for viral adsorption, and then the
viral inoculum was removed. Cells were washed once with PBS,
and the conditioned media replaced. Then the cells were incu-
bated at 37 1C, 5% CO2 overnight, and the supernatant collected
24 hpi and stored at 80 1C until analyzed.
Small molecule inhibitor/activator studies
Small molecules included Ag-126 (Santa Cruz Biotechnology,
Catalogue No. sc-3528), Ceramide C6 (Santa Cruz Biotechnology,
Catalogue no. sc-3527), U0126 (Cell Signaling Technology, Catalo-
gue no. 9903), PD184352 (Selleckchem, Catalogue no. S1020),
GSK1120212 (Selleckchem, Catalogue no. S2673), and AZD6244
(Selleckchem, Catalogue no. S1008). Compounds were dissolved in
dimethyl sulfoxide (DMSO). U87MG cells were seeded in a 96-well
plate at a density of 10,000 cells per well. The next day the cells
were pretreated with the compound for 2 h. Drug concentrations
were maintained in a manner that did not exceed 0.1% DMSO ﬁnal
concentration per well. The conditioned media containing the
compound were removed and viral infections proceeded at multi-
plicity of infection (MOI) of 0.1 for 1 h at 37 1C. The viral inocula
were then removed and replaced with the conditioned media with
compound. The cells were incubated for 24 h at 37 1C, 5% CO2, and
the supernatant was collected and stored at 80 1C until analyzed.
Cell viability assays
Cell viability was measured using a Cell-Titer-Glo Luminescent
Cell Viability kit (Promega, Catalog no. G7570) according to the
manufacturer's instructions. Brieﬂy, U87MG cells were seeded in
96-well white wall plates at 10,000 cells per well and incubated
for 24 h at 37 1C, 5% CO2. Cells were then treated with Ag-126 or
DMSO (control) and incubated for 24 h at 37 1C, 5% CO2. To
determine cell viability, Cell-Titer-Glo reagent was added to the
cells in a ratio of 1:1. The plate was shaken for 2 min at room
temperature and then incubated for 10 min at room temperature.
Luminescence was detected using the DTX 880 multimode detec-
tor (Beckman Coulter).
Reverse phase protein microarray (RPPA)
The methods for RPPA have been described previously (Popova
et al., 2010a, 2010b). U87MG cells were plated in a 6-well format
and infected with TC-83 (MOI:1) for one hour at 37 1C, 5% CO2.
After 6 h, the cells were washed with 1 PBS, lysed and boiled for
10 min. The lysis buffer composition is as follows: 1:1 mixture of
T-PER Reagent (Pierce, IL) and 2 Tris–glycine SDS sample buffer
(Novex, Invitrogen, CA) in the presence of 2.5% β -mercaptoetha-
nol, and protease and phosphatase inhibitors (1 Halt cocktail,
Pierce). Lysed samples were stored at 80 1C until they were
ready for the RPPA study. To conduct the RPPA study, approxi-
mately 30–50 nl of each sample were printed onto nitrocellulose
slides (Whatman, MA) using a high-resolution 2470 arrayer
(Aushon Biosystems, Billerica, MA). Randomly chosed slides were
stained with CyproRuby stain to quantify total protein which will
be used in signal normalization (described below). The printed
slides were stained using a Dako Autostainer with speciﬁc anti-
bodies using a biotin-linked peroxidase-catalyzed signal ampliﬁ-
cation (Dako, CSA kit). The slides were stained with a secondary
biotinylated goat anti-rabbit IgG antibody (Vector Labs, Burlin-
game, CA) and imaged (Umax PowerLook III scanner, Umax, Dallas,
TX). The images were analyzed with software AlphaAse FC (Alpha
Innotech). For every antibody used, the average pixel intensity
value for negative control (staining with second antibody only)
was subtracted from the average pixel intensity value and normal-
ized by the corresponding average value of the total protein
intensity. The signal intensity for every antibody spot was statis-
tically evaluated using GraphPad Prism ver5 software (Graphpad
Software, CA). The antibodies used in RPPA array were against the
following phosphorylated proteins and purchased from Cell Sig-
naling: (catalog numbers of antibodies indicated in parenthesis):
B-Raf c-Raf ERK (9101), MEK1/2 (9121), p65 (3031), p90RSK
(9341), RSK3 (9348), STAT1 (9134),
Assays to observe cytopathic effects (CPE)
U87MG cells were seeded at a density of 1.0105cells per well
in a 12-well plate. Cells were mock-treated, treated with Ag-126,
or treated with Ag-126 for 2 h and then infected for 1 h. Each
condition was performed in triplicate wells. Random sections of
each well were imaged at 24 hpi and 48 hpi using a Zeiss
AXIOVERT-25 microscope with Pixera's Viewﬁnder 3.0 software.
Plaque assays
VERO cells were seeded at a density of 1.5105cells per well in
a 12-well plate. Viral supernatants, diluted in DMEM, were used to
infect VERO cells in technical duplicate. The plates were incubated
at 37 1C and 5% CO2 for 1 h with occasional rocking. A 1 ml overlay
comprised of 2XE-MEM and 0.6% agarose (1:1) was added to each
of the wells. Once solidiﬁed the plates were incubated for an
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additional 48 h at 37 1C and 5% CO2. To complete the assay, an
addition of a 10% Formaldehyde solution was added to the surface
of the agarose plugs followed by 1 h incubation at room tempera-
ture. The plates were then rinsed with diH2O and the agarose
plugs removed. A 1% crystal violet solution containing 20% ethanol
was added to each of the wells and incubated at room temperature
with rocking for 30 min. The plates were rinsed with diH2O, and
visible plaques counted to determine viral titers as plaque forming
units per ml (PFU/ml).
Modiﬁed plaque reduction neutralization assay
TC-83 viral stock at 1.6107 PFU/ml was incubated at room
temperature for 1 h either in the presence or absence of 10 μM Ag-
126 with gentle mixing. Samples were then directly subjected to
plaque assay.
Protein extract preparations for western blot analysis
In order to obtain whole cell lysates, the media was removed
from U87MG cells and the cells were washed once with PBS. Next
the cells were lysed with lysis buffer that consisted of a 1:1
mixture of T-PER reagent (Pierce, Catalogue no. 78510), 2 Tris–
glycine SDS sample buffer (Invitrogen, Catalogue no. LC2676), 2.5%
β-mercaptoethanol, and protease and phosphatase inhibitor cock-
tail (1 Halt mixture, Pierce). Cells with lysis buffer were
incubated at room temperature for one minute, and then collected.
Cell lysates were boiled for 10 min and stored at 80 1C until
analyzed.
Quantitative RT-PCR (q-RT-PCR)
U87MG cells were pre-treated with 1 μM Ceramide C6 or
10 μM Ag126 for 2 h and then infected with TC-83 at an MOI:
0.1. As a control cells were treated with DMSO. At 16 h post
infection cells were lysed using the MagMAX™-96 Total RNA
Isolation Kit (Life Technologies, AM1830) as per the manufacturer's
instructions. Intracellular viral RNA was quantitated using q-RT-
PCR with primers and probe for nucleotides 7931–8005 of VEEV
TC-83 (Kehn-Hall et al., 2012). The q-RT-PCR cycling conditions
were as follows: 1 cycle at 50 1C for 30 min, 1 cycle at 95 1C for
2 min and 40 cycles at 95 1C for 15 s and 61 1C for 1 min using
the StepOne Plus Real Time PCR system. The primer and probe
pairs used were originally described by Julander; forward primer
(TCTGACAAGACGTTCCCAATCA) and reverse primer (GAATAACTT
CCCTCCGACCACA) and Taqman probe (50 6-carboxyﬂuorescein-
TGTTGGAAGGGAAGATAAACGGCTACGC-6-carboxy- N,N,N0,N0-tet-
ramethylrhodamine-30) (Julander et al., 2008). The q-RT-PCR
assays were performed using BioRad iTaq Universal Probes one-
step 2 mix (BioRad, 172–5140). The absolute quantiﬁcation was
calculated based on the threshold cycle (Ct) relative to the
standard curve.
Western blot analysis
Whole cell lysates were separated on a 4–20% Tris–Glycine Gel
at 100 V and transferred to a polyvinyl diﬂuoride (PVDF) mem-
brane using the iBlot gel transfer system (Invitrogen). The mem-
branes were blocked in 1% dry milk in PBS-Tween 20 or 2% BSA in
PBS-Tween 20 at room temperature. Primary antibodies to VEEV
Capsid (BEI Resources, NR 9403), VEEV Glycoprotein (BEI
Resources, NR 9404), p-ERK 1/2 (Thr 202/Tyr 204) (Cell Signaling
Technology, Catalogue no. 4370), ERK 1/2 Antibody (Cell Signaling
Technology, Catalogue no. 9102), p-p90RSK (Ser380) (Cell Signal-
ing Technology, Catalogue no. 11,989) and HRP-conjugated actin
(Abcam, Catalogue no. ab49900) were used according to
manufacturer's instructions. The blots were incubated with pri-
mary antibody overnight at 4 1C. Following 2 washes with PBS-
Tween 20 the blots were then incubated with respective second-
ary HRP-coupled antibody for 2 h. After 3 washes with PBS-Tween
20 and 1 wash with PBS, the membranes were visualized by
chemiluminescence using SuperSignal West Femto Maximum
Sensitivity Substrate Kit (ThermoScientiﬁc) on a BIO- RAD Mole-
cular Imager ChemiDoc XRS system (BIO-RAD).
Immunoﬂuorescence
U87MG cells were seeded at a density of 20,000 cells/well in an
8-well chambered slide. The cells were either, mock-treated,
treated with 10 μM Ag-126 or infected with TC-83 at an MOI of
5. Cells were ﬁxed with 4% paraformaldehyde for 20 min and
permeabilized with 0.5% Triton X-100 in PBS for 15 min. Slides
were washed with PBS and blocked at room temperature for
10 min with 3% BSA. The slides were incubated with primary
antibody for 1 h in the dark at 37 1C, and then washed three times
with PBS and incubated with respective secondary antibody Alexa
Fluor antibodies (Invitrogen) for 1 h in the dark at 37 1C. Primary
antibody markers for the endoplasmic reticulum and golgi
included PDI (C81H6) and RCAS1 (D2B6N), respectively (Cell
Signaling Technology, Catalogue no. 8653S). Slides were washed
three times with PBS and incubated with DAPI for 10 min in the
dark at room temperature. Following an additional PBS wash, the
slides were mounted with Fluoromount G (SouthernBiotech,
Catalogue no. 0100-01) and stored in the dark at 4 1C overnight.
The cells were imaged using Nikon Eclipse TE2000-U. Images were
taken at 60 objective.
Statistical analysis
Graphing and data analyses were performed using the R
Statistical Language. We performed three independent experi-
ments using separately harvested viral supernatants each time.
Each experiment included three biological samples per group. We
recorded the raw plaque counts for each of the plaque assays and
determined the PFU/ml. The ﬁgures present scatter plots overlaid
on box and whisker plots. The box and whisker plots have their
conventional meanings. We use our graphical representations as
well as performing Wilcoxon rank sum tests to assess differences
among treatment groups. P-values less than 0.01 were considered
statistically signiﬁcant. Signiﬁcant results are indicated on the
ﬁgures in the following fashion: P-valuer0.0001 (nnn), P-value
r0.001 (nn), P-valuer0.01 (n).
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